丁蔻理中汤对中晚期胃癌化疗患者细胞免疫因子及不良反应的影响  

Effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy

作　　者：杨爱武[1] 林志敏[1] 张江灵[1] 梁仁佩 郑维斌[1] Yang Aiwu;Lin Zhimin;Zhang Jiangling;Liang Renpei;Zheng Weibin(Department of Oncology Medicine, 180th Hospital of People＇s Liberation Army of Fujian Province, Quanzhou 362000, China)

机构地区：[1]福建省泉州市解放军第180医院肿瘤内科,362000

出　　处：《国际肿瘤学杂志》2018年第3期161-165,共5页Journal of International Oncology

摘　　要：目的 探讨丁蔻理中汤对中晚期胃癌化疗患者细胞免疫因子及不良反应的影响。方法 选取2014年10月—2016年12月我院收治的中晚期胃癌患者138例，采用随机数字表法将其随机分为对照组（n=69）和观察组（n=69）。对照组给予FOLFOX4化疗方案（奥沙利铂＋亚叶酸钙＋氟尿嘧啶）进行治疗，观察组在对照组的基础上给予丁蔻理中汤治疗。均于治疗前后抽取患者外周静脉血，检测并对比细胞免疫因子CD3＋、CD4＋、CD8＋、CD4＋/CD8＋，并观察两组患者临床疗效及不良反应发生情况。结果 观察组治疗后完全缓解（CR）、部分缓解（PR）、稳定（SD）、进展（PD）分别有16、25、16、12例，对照组CR、PR、SD、PD分别有9、20、19、21例，两组患者临床疗效比较差异有统计学意义（Z=4.381，P=0.036）；且与对照组相比，观察组临床获益率（CBR）明显提高（59.42%∶42.03%），差异有统计学意义（χ2=4.175，P=0.041）。观察组患者治疗前后细胞免疫因子CD3＋［（52.67±6.21）%∶（53.45±6.54）%］、CD4＋［（23.56±3.85）%∶（24.09±2.91）%］、CD8＋［（28.16±3.49）%∶（27.87±3.26）%］、CD4＋/CD8＋（1.13±0.27∶1.19±0.31）差异均无统计学意义（t=0.718，P=0.474；t=0.912，P=0.363；t=0.504，P=0.615；t=1.212，P=0.227），但对照组患者治疗后细胞免疫因子CD3＋［（50.36±3.74）%∶（53.13±6.12）%］、CD4＋［（21.26±2.37）%∶（23.44±3.96）%］、CD4＋/CD8＋（0.96±0.26∶1.15±0.25）较治疗前均明显降低，CD8＋［（31.64±4.05）%∶（27.98±3.52）%］较治疗前明显提高，差异均具有统计学意义（t=3.208，P＜0.001；t=3.924，P＜0.001；t=4.289，P＜0.001；t=5.666，P＜0.001）。与对照组相比，观察组患者治疗后CD3＋［（53.45±6.54）%∶（50.36±3.74）%］、CD4＋［（24.09±2.91）%∶（21.26±2.37）%］、CD4＋/CD8＋（1.19±0.31∶0.96±0.26）均明显提高，且CD8＋Objective To investigate the effects of Dingkoulizhong decoction on cellular immune factors and adverse reactions in patients with advanced gastric cancer treated with chemotherapy. MethodsOne hundred and thirtyeight patients with advanced gastric cancer were enrolled in our hospital from October 2014 to December 2016, and were randomly divided into control group （n=69） and observation group （n=69） by using the random number table. The patients of the control group were treated with FOLFOX4 chemotherapy （oxaliplatin ＋ calcium folinate ＋ fluorouracil）, while the patients of the observation group were given by the treatment of Dingkoulizhong decoction on the basis of the control group. The peripheral blood samples of the patients were collected before and after the treatment. The levels of cellular immune factors CD3＋, CD4＋, CD8＋ and CD4＋/CD8＋ were detected, and the clinical efficacy and adverse reactions of the patients of the two groups were observed. Results After the treatment, the number of complete remission （CR）, partial remission （PR）, stable disease （SD） and progressive disease （PD） in the observation group were 16, 25, 16 and 12 cases respectively, while the control group were 9, 20, 19 and 21 cases respectively, and there was a statistically significant difference in the distribution of clinical efficacy between the two groups （Z=4.381, P=0.036）. Compared with the control group, the clinical benefit rate （CBR） of the observation group was significantly improved （59.42% vs. 42.03%）, with a statistically significant difference （χ2=4.175, P=0.041）. The cellular immune factors CD3＋[（52.67±6.21）% vs. （53.45±6.54）%], CD4＋[（23.56±3.85）% vs. （24.09±2.91）%], CD8＋[（28.16±3.49）% vs. （27.87±3.26）%] and CD4＋/CD8＋ （1.13±0.27 vs. 1.19±0.31） of the patients of the observation group showed no statistically significant difference （t=0.718, P=0.474; t=0.912, P=0.363; t=0.504, P=0.615; t=1.212, P=0.227） before and

关 键 词：胃肿瘤 药物疗法 细胞因子类 丁蔻理中汤 

分 类 号：R735.2[医药卫生—肿瘤]